Biological Immunology

Stelara

Payments companies reported to CMS as associated with Stelara. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$12Massociated payments (2023-2025)
27,583clinicians with associated payments
6companies reporting

By year

2023 $4.8M
2024 $6.7M
2025 $740K

Payments reported as associated with Stelara, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $8.0M
Family $929K
Physician Assistant $616K
Nurse Practitioner $375K
Medical $351K
Adult Health (Nurse Practitioner) $294K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Stelara

These are the largest totals companies reported as associated with Stelara. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Douglas Nguyen Mission Viejo, CA Gastroenterology (Internal Medicine) $224,636.99
Maya Srivastava Williamsville, NY Gastroenterology (Internal Medicine) $210,084.76
Kimberly Kearns Hoffman Estates, IL Adult Health (Nurse Practitioner) $187,274.79
Gerald Dryden Louisville, KY Gastroenterology (Internal Medicine) $173,362.30
Peter Mcnally Ft Carson, CO Gastroenterology (Internal Medicine) $171,661.89
Anish Patel Fort Sam Houston, TX Gastroenterology (Internal Medicine) $171,208.49
Jeevan Vinod New York, NY Gastroenterology (Internal Medicine) $161,976.35
Charles Randall San Antonio, TX Gastroenterology (Internal Medicine) $157,818.65
Mohamed Naem Westlake, OH Gastroenterology (Internal Medicine) $156,560.41
Arthur Kornbluth New York, NY Gastroenterology (Internal Medicine) $149,508.99

Prescribed Stelara?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.